Cerus Corporation Announces New Clinical Trial to Compare Fibrinogen Treatments for Trauma Patients
Reuters
Jul 21
<a href="https://laohu8.com/S/CERS">Cerus Corporation</a> Announces New Clinical Trial to Compare Fibrinogen Treatments for Trauma Patients
Cerus Corporation has announced a new clinical study, CRYO-FIRST, to evaluate the efficacy of pre-thawed INTERCEPT Fibrinogen Complex (IFC) compared to conventional cryoprecipitated antihemophilic factor (CRYO-AHF) in patients experiencing trauma-associated hemorrhagic shock. The study will involve 320 patients and will use hospital cluster randomized treatment blocks to assess the effectiveness of the two FDA-approved blood components. Patients admitted within 60 minutes of a trauma injury and showing low fibrinogen levels will be eligible for the study. The additional funding from the U.S. Department of Defense supports this research, aiming to provide insights into the benefits of early fibrinogen transfusion. The results of the CRYO-FIRST study are expected to offer critical information regarding the treatment of acute trauma patients with fibrinogen deficiency, and findings will be presented in the future.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cerus Corporation published the original content used to generate this news brief via Business Wire (Ref. ID: 20250721154296) on July 21, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.